Skin Cancer

The Skin Cancer Foundation's gala raises over $800,000, featuring Christie Brinkley and highlighting vital skin cancer awareness initiatives and personal stories.

This Melanoma Monday, we take a look at melanoma care in the US, from treatments to persistent gaps in access, early detection, and long-term outcomes.

Patients with mucous membrane pemphigoid face increased skin cancer risks, particularly squamous cell carcinoma, highlighting the need for vigilant screening.

Stage IV melanoma survivors face persistent adverse effects and distress, highlighting the need for targeted psychological support and care.

New findings reveal DecisionDx-Melanoma more accurately identifies patients with under 5% risk of SLN positivity, supporting safer avoidance of SLNB surgery.

New research reveals that early discontinuation of adjuvant immunotherapy for melanoma does not lead to worse outcomes.

New prospective data from the DECIDE study reinforce the role of the 31-GEP test in clinical decision-making.

High response rates and no systemic toxicity in multiple nonmelanoma skin tumors were observed in this vulnerable patient population.

Researchers reported the case of a 28-year-old woman with epidermodysplasia verruciformis who developed SCC on a sun-protected scalp.

Two-sample Mendelian randomization analysis explored lifestyle factors such as sleep, smoking, alcohol consumption, and sedentary behavior.

Nearly half of patients with melanoma experience significant distress, affecting treatment adherence and quality of life.

A study shows active educational interventions improve melanoma detection rates and rule application, with lasting effects over time.

Estrogen therapy and certain diuretics may increase skin cancer risk, highlighting the need for careful patient counseling and sun exposure management.

John Strasswimmer, MD, PhD, spoke on the difficulty of managing adverse effects, the role of interdisciplinary clinical relationships, and the challenges in complex and older patients.

A 30-year-old patient with dermatofibrosarcoma protuberans faced a recurrence after initial surgery. Mohs micrographic surgery was used for precise excision, reducing recurrence risk and improving outcomes.

The expert discussion focused on patient management strategies, treatment modalities, and the role of multidisciplinary collaboration.

An analysis of 70 studies shows that MMS reduces local recurrence to 5.0% compared to 17.7% for WLE in anogenital SCC cases.

Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.

Satisfaction levels rose and recovery outcomes greatly improved with Cicaglocal compared to the placebo.

A dermatology expert panel confirms IGSRT as a safe, effective first-line treatment for select nonmelanoma skin cancer cases.

A recent study found sunscreen use is higher among women but often not reapplied properly.

A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or excessive hair.

Trauma-induced melanocyte implantation can lead to subcutaneous melanoma, mimicking melanoma of unknown primary but with distinct diagnostic criteria.

Study author Erin McClure, MD, discusses how IGSRT offers consistent NMSC recurrence rates across socioeconomic and comorbidity factors, reinforcing its role as a first-line treatment.

High concentrations of particulate matter can potentially lessen the exposure to UV radiation.

As newly appointed Executive Director of the Foundation, Becky Kamowitz is combining public education with clinical needs in the fight against skin cancer.

George Washington University recently earned a Skin Smart Campus designation, championing skin cancer prevention through education, free sunscreen, and UV safety measures.

Three posters supporting VP-315's treatment efficacy and outcomes were presented at the Winter Clinical Miami conference.

Explore the role of immunohistochemical stains in enhancing diagnostic accuracy during Mohs surgery, aiding treatment of challenging skin cancers.

Cemiplimab demonstrated a 68% reduction in recurrence risk for high-risk CSCC in the phase 3 C-POST trial, according to Regeneron’s latest findings.